Stay updated on Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial

Sign up to get notified when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T11:01:41.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    An NIH-wide notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The study record itself is still shown as inaccessible.
    Difference
    1%
    Check dated 2026-10-24T11:12:46.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The revision identifier in the footer changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T12:34:36.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site’s footer revision identifier changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T12:44:40.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, preventing access to the study details and locations. This blocks the core information users rely on to review the trial.
    Difference
    20%
    Check dated 2026-09-19T19:20:36.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The study record now includes an NIH grant/contract attribution (2017) among its identifiers, clarifying funding sources, and the old revision label (Revision: v3.6.5) was removed to reflect the current version (v3.6.6).
    Difference
    0.1%
    Check dated 2026-08-29T19:04:16.000Z thumbnail image

Stay in the know with updates to Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.